---
document_datetime: 2026-02-04 16:55:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sugammadex-amomed.html
document_name: sugammadex-amomed.html
version: success
processing_time: 0.122185
conversion_datetime: 2026-02-09 22:23:35.113865
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Search

- [Medicines](/en/medicines)
    - [Find medicine](/en/medicines)
    - [Therapeutic areas: latest updates](/en/medicines/therapeutic-areas-latest-updates)
    - [Download medicine data](/en/medicines/download-medicine-data)
    - [What we publish on medicines and when](/en/medicines/what-we-publish-medicines-when)
    - [Medicines under evaluation](/en/medicines/medicines-human-use-under-evaluation)
    - [National registers](/en/medicines/national-registers-authorised-medicines)
- [Human regulatory](/en/human-regulatory-overview)
    - [Overview](/en/human-regulatory-overview)
    - [Research and development](/en/human-regulatory-overview/research-development)
    - [Marketing authorisation](/en/human-regulatory-overview/marketing-authorisation)
    - [Post-authorisation](/en/human-regulatory-overview/post-authorisation)
    - [Medical devices](/en/human-regulatory-overview/medical-devices)
    - [Herbal products](/en/human-regulatory-overview/herbal-medicinal-products)
- [Veterinary regulatory](/en/veterinary-regulatory-overview)
    - [Overview](/en/veterinary-regulatory-overview)
    - [Research and development](/en/veterinary-regulatory-overview/research-development-veterinary-medicines)
    - [Marketing authorisation](/en/veterinary-regulatory-overview/marketing-authorisation-veterinary-medicines)
    - [Post-authorisation](/en/veterinary-regulatory-overview/post-authorisation-veterinary-medicines)
- [Committees](/en/committees)
    - [Overview](/en/committees)
    - [How the committees work](/en/committees/how-committees-work)
    - [CHMP](/en/committees/committee-medicinal-products-human-use-chmp)
    - [CVMP](/en/committees/committee-veterinary-medicinal-products-cvmp)
    - [PRAC](/en/committees/pharmacovigilance-risk-assessment-committee-prac)
    - [COMP](/en/committees/committee-orphan-medicinal-products-comp)
    - [HMPC](/en/committees/committee-herbal-medicinal-products-hmpc)
    - [CAT](/en/committees/committee-advanced-therapies-cat)
    - [PDCO](/en/committees/paediatric-committee-pdco)
    - [Working parties and other groups](/en/committees/working-parties-other-groups)
- [News &amp; events](/en/news-events)
    - [Overview](/en/news-events)
    - [News](/en/news)
    - [Events](/en/events/upcoming-events)
    - [What's new](/en/news-events/whats-new)
    - [Committee highlights](/en/news-events/committee-highlights)
    - [Publications](/en/news-and-events/publications)
    - [Press and social media](/en/news-events/press-social-media)
    - [Podcast: Inside EMA](/en/news-events/podcast-inside-ema)
    - [Open consultations](/en/news-events/open-consultations)
    - [RSS feeds](/en/news-events/rss-feeds)
- [Partners &amp; networks](/en/partners-networks)
    - [Overview](/en/partners-networks)
    - [EU partners](/en/partners-networks/eu-partners)
    - [International activities](/en/partners-networks/international-activities)
    - [Patients and consumers](/en/partners-networks/patients-consumers)
    - [Healthcare professionals](/en/partners-networks/healthcare-professionals)
    - [Academia](/en/partners-networks/academia)
    - [Pharmaceutical industry](/en/partners-networks/pharmaceutical-industry)
    - [Networks](/en/partners-networks/networks)
    - [Health technology assessment bodies](/en/partners-networks/health-technology-assessment-bodies)
    - [One Health approach](/en/partners-networks/one-health-approach)
    - [Animal health practitioners](/en/partners-networks/animal-health-practitioners)
    - [One substance - one assessment](/en/partners-networks/one-substance-one-assessment-osoa-eu-collaboration-chemicals-related-data)
- [About us](/en/about-us)
    - [Overview](/en/about-us)
    - [What we do](/en/about-us/what-we-do)
    - [Who we are](/en/about-us/who-we-are)
    - [How we work](/en/about-us/how-we-work)
    - [Fees](/en/about-us/fees-payable-european-medicines-agency)
    - [Support to SMEs](/en/about-us/support-smes)
    - [Annual reports and work programmes](/en/about-us/annual-reports-work-programmes)
    - [History of EMA](/en/about-us/history-ema)
    - [Careers](/en/about-us/careers)
    - [Procurement](/en/about-us/procurement-grants)
    - [Glossaries](/en/about-us/glossaries)
    - [About this website](/en/about-us/about-website)
    - [Data protection and privacy](/en/about-us/data-protection-privacy-ema)
    - [Contacts](/en/about-us/contacts-european-medicines-agency)

1. [Home](/en/homepage)
2. [Medicines](https://www.ema.europa.eu/en/medicines)
3. Sugammadex Amomed

# Sugammadex Amomed

[RSS](/en/individual-human-medicine.xml/67642)

##### Authorised

This medicine is authorised for use in the European Union

sugammadex Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sugammadex Amomed](#news-on)
- [More information on Sugammadex Amomed](#more-information-on-sugammadex-amomed-1638)
- [Product information - with tracked changes](#product-information-with-tracked-changes-83295)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sugammadex Amomed is a medicine used to reverse the effect of the muscle relaxants rocuronium and vecuronium. Muscle relaxants are medicines used during some types of operation to make the muscles relax, including the muscles that help the patient to breathe. Muscle relaxants make it easier for the surgeon to do the operation. Sugammadex Amomed is used to speed up the recovery from the muscle relaxant, usually at the end of the operation.

Sugammadex Amomed can be used in adults who have received rocuronium and vecuronium, and in children from birth who have received rocuronium.

Sugammadex Amomed contains the active substance sugammadex and is a 'generic medicine'. This means that Sugammadex Amomed contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Sugammadex Amomed is Bridion.

Expand section

Collapse section

## How is Sugammadex Amomed used?

Sugammadex Amomed can only be obtained with a prescription. It is given by or under the supervision of an anaesthetist (a doctor specialised in anaesthesia). Sugammadex Amomed is given into a vein as a single bolus injection (given all at once).

For more information about using Sugammadex Amomed, see the package leaflet or contact your doctor or pharmacist.

## How does Sugammadex Amomed work?

The active substance in Sugammadex Amomed, sugammadex, attaches to the muscle relaxants rocuronium and vecuronium stopping them from having an effect. As a result, the muscles contract and begin to work normally again, including the muscles that help the patient to breathe.

## How has Sugammadex Amomed been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Bridion, and do not need to be repeated for Sugammadex Amomed.

As for every medicine, the company provided data on the quality of Sugammadex Amomed. There was no need for 'bioequivalence' studies to investigate whether Sugammadex Amomed is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Sugammadex Amomed is given by injection into a vein, so the active substance is delivered straight into the bloodstream.

## What are the benefits and risks of Sugammadex Amomed?

Because Sugammadex Amomed is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Sugammadex Amomed authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Sugammadex Amomed has been shown to be comparable to Bridion. Therefore, the Agency's view was that, as for Bridion, the benefits of Sugammadex Amomed outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sugammadex Amomed?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sugammadex Amomed have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sugammadex Amomed are continuously monitored. Suspected side effects reported with Sugammadex Amomed are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sugammadex Amomed

Sugammadex Amomed received a marketing authorisation valid throughout the EU on 10 January 2023.

Sugammadex Amomed : EPAR - Medicine overview

Reference Number: EMADOC-1829012207-25025

English (EN) (132.28 KB - PDF)

**First published:** 13/01/2023

**Last updated:** 24/07/2025

[View](/en/documents/overview/sugammadex-amomed-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-317)

български (BG) (155.79 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/bg/documents/overview/sugammadex-amomed-epar-medicine-overview_bg.pdf)

español (ES) (132.89 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/es/documents/overview/sugammadex-amomed-epar-medicine-overview_es.pdf)

čeština (CS) (154.57 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/cs/documents/overview/sugammadex-amomed-epar-medicine-overview_cs.pdf)

dansk (DA) (132.9 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/da/documents/overview/sugammadex-amomed-epar-medicine-overview_da.pdf)

Deutsch (DE) (136.03 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/de/documents/overview/sugammadex-amomed-epar-medicine-overview_de.pdf)

eesti keel (ET) (130.75 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/et/documents/overview/sugammadex-amomed-epar-medicine-overview_et.pdf)

ελληνικά (EL) (156.11 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/el/documents/overview/sugammadex-amomed-epar-medicine-overview_el.pdf)

français (FR) (133.57 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/fr/documents/overview/sugammadex-amomed-epar-medicine-overview_fr.pdf)

hrvatski (HR) (152.2 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/hr/documents/overview/sugammadex-amomed-epar-medicine-overview_hr.pdf)

italiano (IT) (131.81 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/it/documents/overview/sugammadex-amomed-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (161.49 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/lv/documents/overview/sugammadex-amomed-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (152.2 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/lt/documents/overview/sugammadex-amomed-epar-medicine-overview_lt.pdf)

magyar (HU) (154.84 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/hu/documents/overview/sugammadex-amomed-epar-medicine-overview_hu.pdf)

Malti (MT) (154.57 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/mt/documents/overview/sugammadex-amomed-epar-medicine-overview_mt.pdf)

Nederlands (NL) (133.92 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/nl/documents/overview/sugammadex-amomed-epar-medicine-overview_nl.pdf)

polski (PL) (159.11 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/pl/documents/overview/sugammadex-amomed-epar-medicine-overview_pl.pdf)

português (PT) (133.13 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/pt/documents/overview/sugammadex-amomed-epar-medicine-overview_pt.pdf)

română (RO) (150.59 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/ro/documents/overview/sugammadex-amomed-epar-medicine-overview_ro.pdf)

slovenčina (SK) (154.07 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/sk/documents/overview/sugammadex-amomed-epar-medicine-overview_sk.pdf)

slovenščina (SL) (151.47 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/sl/documents/overview/sugammadex-amomed-epar-medicine-overview_sl.pdf)

Suomi (FI) (130.81 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/fi/documents/overview/sugammadex-amomed-epar-medicine-overview_fi.pdf)

svenska (SV) (130.77 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

24/07/2025

[View](/sv/documents/overview/sugammadex-amomed-epar-medicine-overview_sv.pdf)

Sugammadex Amomed : EPAR - Risk Management Plan

English (EN) (171.98 KB - PDF)

**First published:** 13/01/2023

**Last updated:** 25/06/2025

[View](/en/documents/rmp/sugammadex-amomed-epar-risk-management-plan_en.pdf)

## Product information

Sugammadex Amomed : EPAR - Product information

English (EN) (602.92 KB - PDF)

**First published:** 13/01/2023

**Last updated:** 04/02/2026

[View](/en/documents/product-information/sugammadex-amomed-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-111)

български (BG) (544.61 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/bg/documents/product-information/sugammadex-amomed-epar-product-information_bg.pdf)

español (ES) (430.11 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/es/documents/product-information/sugammadex-amomed-epar-product-information_es.pdf)

čeština (CS) (491.38 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/cs/documents/product-information/sugammadex-amomed-epar-product-information_cs.pdf)

dansk (DA) (450.16 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/da/documents/product-information/sugammadex-amomed-epar-product-information_da.pdf)

Deutsch (DE) (486.39 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/de/documents/product-information/sugammadex-amomed-epar-product-information_de.pdf)

eesti keel (ET) (477.5 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/et/documents/product-information/sugammadex-amomed-epar-product-information_et.pdf)

ελληνικά (EL) (518.03 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/el/documents/product-information/sugammadex-amomed-epar-product-information_el.pdf)

français (FR) (481.23 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/fr/documents/product-information/sugammadex-amomed-epar-product-information_fr.pdf)

hrvatski (HR) (497.09 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/hr/documents/product-information/sugammadex-amomed-epar-product-information_hr.pdf)

íslenska (IS) (430.96 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/is/documents/product-information/sugammadex-amomed-epar-product-information_is.pdf)

italiano (IT) (465.21 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/it/documents/product-information/sugammadex-amomed-epar-product-information_it.pdf)

latviešu valoda (LV) (478.33 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/lv/documents/product-information/sugammadex-amomed-epar-product-information_lv.pdf)

lietuvių kalba (LT) (483.98 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/lt/documents/product-information/sugammadex-amomed-epar-product-information_lt.pdf)

magyar (HU) (527.53 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/hu/documents/product-information/sugammadex-amomed-epar-product-information_hu.pdf)

Malti (MT) (522.98 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/mt/documents/product-information/sugammadex-amomed-epar-product-information_mt.pdf)

Nederlands (NL) (455.78 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/nl/documents/product-information/sugammadex-amomed-epar-product-information_nl.pdf)

norsk (NO) (460.03 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/no/documents/product-information/sugammadex-amomed-epar-product-information_no.pdf)

polski (PL) (518.54 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/pl/documents/product-information/sugammadex-amomed-epar-product-information_pl.pdf)

português (PT) (480.91 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/pt/documents/product-information/sugammadex-amomed-epar-product-information_pt.pdf)

română (RO) (485.76 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/ro/documents/product-information/sugammadex-amomed-epar-product-information_ro.pdf)

slovenčina (SK) (527.37 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/sk/documents/product-information/sugammadex-amomed-epar-product-information_sk.pdf)

slovenščina (SL) (517.21 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/sl/documents/product-information/sugammadex-amomed-epar-product-information_sl.pdf)

Suomi (FI) (435.99 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/fi/documents/product-information/sugammadex-amomed-epar-product-information_fi.pdf)

svenska (SV) (442.44 KB - PDF)

**First published:**

13/01/2023

**Last updated:**

04/02/2026

[View](/sv/documents/product-information/sugammadex-amomed-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000323967 02/02/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sugammadex Amomed : EPAR - All Authorised presentations

English (EN) (45.89 KB - PDF)

**First published:** 13/01/2023

[View](/en/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-691)

български (BG) (63.07 KB - PDF)

**First published:**

13/01/2023

[View](/bg/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_bg.pdf)

español (ES) (46.42 KB - PDF)

**First published:**

13/01/2023

[View](/es/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_es.pdf)

čeština (CS) (61.51 KB - PDF)

**First published:**

13/01/2023

[View](/cs/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (48.56 KB - PDF)

**First published:**

13/01/2023

[View](/da/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (48.42 KB - PDF)

**First published:**

13/01/2023

[View](/de/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (45.82 KB - PDF)

**First published:**

13/01/2023

[View](/et/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (61 KB - PDF)

**First published:**

13/01/2023

[View](/el/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_el.pdf)

français (FR) (47 KB - PDF)

**First published:**

13/01/2023

[View](/fr/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (63.38 KB - PDF)

**First published:**

13/01/2023

[View](/hr/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (47.82 KB - PDF)

**First published:**

13/01/2023

[View](/is/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.12 KB - PDF)

**First published:**

13/01/2023

[View](/it/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (63.73 KB - PDF)

**First published:**

13/01/2023

[View](/lv/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (64.9 KB - PDF)

**First published:**

13/01/2023

[View](/lt/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (54.69 KB - PDF)

**First published:**

13/01/2023

[View](/hu/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (64.99 KB - PDF)

**First published:**

13/01/2023

[View](/mt/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (48.36 KB - PDF)

**First published:**

13/01/2023

[View](/nl/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (48.24 KB - PDF)

**First published:**

13/01/2023

[View](/no/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_no.pdf)

polski (PL) (66.58 KB - PDF)

**First published:**

13/01/2023

[View](/pl/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_pl.pdf)

português (PT) (47.4 KB - PDF)

**First published:**

13/01/2023

[View](/pt/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_pt.pdf)

română (RO) (61.28 KB - PDF)

**First published:**

13/01/2023

[View](/ro/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (65.17 KB - PDF)

**First published:**

13/01/2023

[View](/sk/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (54.23 KB - PDF)

**First published:**

13/01/2023

[View](/sl/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (45.75 KB - PDF)

**First published:**

13/01/2023

[View](/fi/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.19 KB - PDF)

**First published:**

13/01/2023

[View](/sv/documents/all-authorised-presentations/sugammadex-amomed-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sugammadex Amomed Active substance sugammadex sodium International non-proprietary name (INN) or common name sugammadex Therapeutic area (MeSH) Neuromuscular Blockade Anatomical therapeutic chemical (ATC) code V03AB35

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

Reversal of neuromuscular blockade induced by rocuronium or vecuronium.

For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in paediatric patients from birth to 17 years.

## Authorisation details

EMA product number EMEA/H/C/005935

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

AOP Orphan Pharmaceuticals GmbH

Leopold-Ungar-Platz 2

Opinion adopted 10/11/2022 Marketing authorisation issued 10/01/2023 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sugammadex Amomed : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (625.3 KB - PDF)

**First published:** 25/03/2025

**Last updated:** 04/02/2026

[View](/en/documents/procedural-steps-after/sugammadex-amomed-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sugammadex Amomed : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (102.32 KB - PDF)

**First published:** 06/07/2023

**Last updated:** 23/09/2024

[View](/en/documents/procedural-steps-after/sugammadex-amomed-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Sugammadex Amomed : EPAR - Public assessment report

Reference Number: EMA/CHMP/906354/2022

English (EN) (331.46 KB - PDF)

**First published:** 13/01/2023

[View](/en/documents/assessment-report/sugammadex-amomed-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sugammadex Amomed

Reference Number: EMA/CHMP/855683/2022

English (EN) (150.21 KB - PDF)

**First published:** 11/11/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sugammadex-amomed_en.pdf)

#### News on Sugammadex Amomed

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022) 11/11/2022

#### More information on Sugammadex Amomed

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-198)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Sugammadex Amomed : EPAR - Product information - tracked changes

English (EN) (88.85 KB - DOCX)

**First published:** 04/02/2026

[View](/en/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-824)

български (BG) (106.9 KB - DOCX)

**First published:**

04/02/2026

[View](/bg/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_bg.docx)

español (ES) (108.29 KB - DOCX)

**First published:**

04/02/2026

[View](/es/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_es.docx)

čeština (CS) (105.54 KB - DOCX)

**First published:**

04/02/2026

[View](/cs/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (88.82 KB - DOCX)

**First published:**

04/02/2026

[View](/da/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (107.45 KB - DOCX)

**First published:**

04/02/2026

[View](/de/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (101.66 KB - DOCX)

**First published:**

04/02/2026

[View](/et/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (120.4 KB - DOCX)

**First published:**

04/02/2026

[View](/el/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_el.docx)

français (FR) (94.07 KB - DOCX)

**First published:**

04/02/2026

[View](/fr/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (99.4 KB - DOCX)

**First published:**

04/02/2026

[View](/hr/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (99.75 KB - DOCX)

**First published:**

04/02/2026

[View](/is/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_is.docx)

italiano (IT) (101.15 KB - DOCX)

**First published:**

04/02/2026

[View](/it/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (103.15 KB - DOCX)

**First published:**

04/02/2026

[View](/lv/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (104.86 KB - DOCX)

**First published:**

04/02/2026

[View](/lt/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (100.97 KB - DOCX)

**First published:**

04/02/2026

[View](/hu/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (102.14 KB - DOCX)

**First published:**

04/02/2026

[View](/mt/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (84.29 KB - DOCX)

**First published:**

04/02/2026

[View](/nl/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (84.91 KB - DOCX)

**First published:**

04/02/2026

[View](/no/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_no.docx)

polski (PL) (99.66 KB - DOCX)

**First published:**

04/02/2026

[View](/pl/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_pl.docx)

português (PT) (87.85 KB - DOCX)

**First published:**

04/02/2026

[View](/pt/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_pt.docx)

română (RO) (94.54 KB - DOCX)

**First published:**

04/02/2026

[View](/ro/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (95.15 KB - DOCX)

**First published:**

04/02/2026

[View](/sk/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (86.04 KB - DOCX)

**First published:**

04/02/2026

[View](/sl/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (105.83 KB - DOCX)

**First published:**

04/02/2026

[View](/fi/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (83.9 KB - DOCX)

**First published:**

04/02/2026

[View](/sv/documents/product-information-tracked-changes/sugammadex-amomed-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 04/02/2026

## Share this page

[Back to top](#main-content)